Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.

Also called NCT04603508

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
EMS (from the registry)
Registry
  • NCT NCT04603508
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04603508. Randomized; double masking; primary purpose treatment. Start 2023-03 (anticipated); primary completion 2025-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia
Condition
Type 2 Diabetes Mellitus
Condition
Dyslipidemia
Intervention (Drug)
BERLIM 25/10 association
Intervention (Drug)
EMPAGLIFLOZIN
Intervention (Drug)
ROSUVASTATIN CALCIUM
Intervention (Other)
BERLIM 25/10 ASSOCIATION PLACEBO
Intervention (Other)
EMPAGLIFLOZIN PLACEBO
Intervention (Other)
ROSUVASTATIN CALCIUM PLACEBO
Lead sponsor
EMS (class: industry)

Record details

Record id
cardio:ct-nct04603508
Content hash
8236cb1530655dfa1bb7cc4068a5f5a6a5282fc620b119f1315ea8b0c66ed681